and ERBB2 in 141 primary tumors and investigated the role of t-DARPP in trastuzumab resistance using OE19 and OE33 EAC cell models. Overexpression of t-DARPP mRNA was detected in two-thirds of tumors with a correlation between ERBB2 and t-DARPP overexpression levels (r=0.58, p=0.003).
Introduction
Esophageal carcinoma is the sixth most common cause of cancer-related death worldwide (1) . Histologically, esophageal cancer can be divided into adenocarcinoma and squamous cell carcinoma. The incidence of esophageal adenocarcinoma (EAC) has been rising fast in the past three decades (2, 3) . There are approximately 14,000 cases of esophageal cancer per year in the United States, most of which are EAC (4, 5) . The overall 5 year survival rate of EAC is less than 15% (4-7), suggesting that current treatment regimens are ineffective.
Chromosomal amplification at the 17q21 region is a frequent finding in adenocarcinomas of the stomach and esophagus (8, 9) . This region is a gene-rich area that contains several candidate cancer genes (9) . The ERBB2 locus, within the 17q12-q21 amplicon, has been heavily implicated in several malignancies. ERBB2 is amplified and overexpressed in approximately 15-25% of EAC tumor specimens and has been implicated in the pathogenesis of EAC (10) (11) (12) . In addition to ERBB2, the amplicon region contains several other genes such as DARPP-32 (also known as protein phosphatase 1 regulatory subunit 1B (PPP1R1B), GRB7 and TOP2A. Recently, DARPP-32 and its cancer-specific truncated variant (t-DARPP) have been mapped to the ERBB2 amplicon (8) . t-DARPP is overexpressed in several malignancies, such as those of the stomach, colon, breast, and prostate (13) (14) (15) . We and others have shown that t-DARPP protein promotes cell growth, survival, and drug resistance through activation of AKT signaling in cancer cells (14, (16) (17) (18) .
The ERBB2 gene-targeted therapy continues to be applied in several clinical trials; Trastuzumab (Herceptin), a humanized monoclonal anti-ERBB2 antibody, was first used for the treatment of ERBB2-overexpressing advanced metastatic breast cancers (19) . To date, most of our understanding of ERBB2-targted therapy comes from studies in breast cancer. Although ERBB2-positive tumors initially respond to trastuzumab treatment, the majority of responders progress within 12 months of initiating therapy as a result of acquired trastuzumab resistance (20) . Several studies have elucidated some of the mechanisms of trastuzumab resistance using in vitro cell models. This resistance has been attributed to disruption of interaction between ERBB2 and trastuzumab by MUC4 expression (21); compensatory signaling by other ERBB receptor members (22) ; compensatory signaling from other types of receptors such as IGF-IR (23); increased circulating ERBB2 ECD (24) ; and altered downstream signaling, including PTEN deficiency (25) , increased AKT activity (26) , and downregulation of P27 (CDKN1B) (27) .
Trastuzumab in combination with Cisplatin has been recently used in clinical trials to treat patients with ERBB2-positive metastatic gastric or gastroesophageal junction adenocarcinoma (28) .
Of note, a phase III clinical trial (RTOG 1010 protocol) is currently underway to evaluate the addition of trastuzumab to increase disease-free survival when combined with trimodality treatment (radiation plus chemotherapy followed by surgery) for EAC patients. Therefore, it is crucial to characterize novel mechanisms of trastuzumab resistance in EAC as our capabilities to identify, overcome or clinically manage this resistant phenotype in EAC are currently limited. In this study, we elucidate a novel mechanism by which t-DARPP mediates trastuzumab resistance in EAC. We demonstrate that t-DARPP binds and stabilizes the ERBB2 protein, thereby activating the AKT signaling and promoting trastuzumab resistance by interfering with trastuzumab interaction with the ERBB2 receptor.
Materials and Methods

Cell lines and reagents
The human esophageal adenocarcinoma cancer cell lines, OE19 and OE33, were obtained from the European Collection of Animal Cell Cultures (Sigma-Aldrich), and ATCC, respectively. To generate trastuzumab-resistant clones, OE19 cells were cultured with increasing concentrations of trastuzumab for over 6 months in vitro and the resistant cells were maintained with 20 μg/ml trastuzumab in culture. Cycloheximide was purchased from Sigma-Aldrich. ERBB2, AKT, p-AKT(S473), caspase-3, cleaved caspase-3, and ɴ-actin antibodies were obtained from Cell Signaling Technology (Danvers, MA). DARPP-32 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and P-ERBB2(Y1248) antibody was obtained from Abcam (San Francisco, CA). Trastuzumab was purchased from the Vanderbilt University Hospital Pharmacy (Nashville, TN).
t-DARPP expression and small-interfering RNA
To generate stable expression cells, the flag-tagged coding sequence of t-DARPP was amplified and cloned into pcDNA3 mammalian expression vector (Invitrogen). OE19 cells stably expressing t-DARPP or pcDNA3 empty vector were generated following standard protocols as described previously (16) . Flag-tagged t-DARPP coding sequence was amplified and cloned into the The CellTiter-Glo Luminescent Cell Viability Assay (Promega) was performed according to supplier instructions. Briefly, cells ( for each treatment condition were normalized to ɴ-actin. The protein degradation curve was generated by plotting band intensities ratios as a function of the time period of CHX treatment.
Linear regression was performed and the protein half-life (t½), which is expressed as the time for degradation of 50% of the protein, was calculated from the fitted line equation (29) . min at 4°C with lysis buffer (1% Triton X-100) containing 1% Halt protease inhibitor cocktail (Thermo Fisher Scientific). Total protein (200 ʅg) was incubated with 50 ʅl Dynabeads Protein G (Invitrogen) in an Eppendorf tube for 1 h at 4°C on a rotating platform to pull down specifically trastuzumab-bound ERBB2 protein. The tubes were placed in a magnetic stand and supernatants were discarded. The beads were then processed and the bound protein was eluted as described above. Protein bands intensities were semi-quantitatively analyzed by densitometry using ImageJ software (NIH Image).
Quantitative real-time RT-PCR
Pulled-down ERBB2 protein bands intensities were depicted as ratios relative to their corresponding input ERBB2 proteins.
Nude mice xenograft experiments
Five-week-old female athymic nude -Foxn1 nu/nu mice (Harlan Laboratories Inc., IN) were purchased and maintained under specific pathogen-free conditions. The mice were randomized into two groups (10 xenografts To establish cell models for investigating the role of t-DARPP in trastuzumab resistance in esophageal adenocarcinoma, we evaluated survival of two esophageal adenocarcinoma cell lines, OE19 and OE33, in response to trastuzumab. The results of the trypan blue dye exclusion assay indicated that OE33 cells were more resistant to trastuzumab than OE19 cells (p<0.001) as treatment with 20 ʅg/ml or 60 ʅg/ml trastuzumab decreased the survival by 70% in OE19 cells as opposed to 40% in OE33 cells ( Figure 1D, left panel) . In addition, the results showed that 20 ʅg/ml trastuzumab was a saturation concentration as a higher drug concentration (60 ʅg/ml) had a similar effect on survival in the two cell lines. The Western blot analysis data showed that both OE19 and OE33 cells have high protein expression levels of ERBB2, which is in line with the reported increased copy numbers of ERBB2 gene in these two cell lines ( Figure 1D , right panel). While t-DARPP protein was highly expressed in OE33 cells, it was undetectable in OE19 cells ( Figure 1D , right panel), suggesting that t-DARPP expression was associated with increased trastuzumab resistance in esophageal cancer cells.
t-DARPP promotes cell survival in esophageal adenocarcinoma
The CellTiter-Glo® viability assay results showed that transiently expressed t-DARPP increased cell survival by 40% relative to control cells in response to trastuzumab (p<0.001) (Figure 2A To confirm the short-term assay results, we performed long-term clonogenic survival assay using the two OE19 cell models. The results indicated that stable expression of t-DARPP doubled the cell survival relative to control (p<0.001) in response to trastuzumab ( Figure 2D ). Moreover, endogenous expression of t-DARPP in resistant cells tripled the cell survival relative to parental cells (p<0.01) in response to trastuzumab ( Figure 2E ). These results demonstrate that t-DARPP expression enhanced cell survival in response to trastuzumab in esophageal adenocarcinoma cells.
t-DARPP inhibits trastuzumab-dependent apoptosis and activation of caspase-3
The Annexin-V staining and FACS analysis results showed that adenoviral transient expression of t-DARPP suppressed early apoptosis events by approximately 25% relative to control in response to trastuzumab (P<0.02) ( Figure 3A) . Accordingly, Western blot analysis data revealed the cleaved caspase-3 form in control cells, but not in t-DARPP-expressing cells following treatment with trastuzumab ( Figure 3B) . Similarly, endogenous expression of t-DARPP in the resistant cells did not lead to an increase in apoptosis as compared to non-treated cells whereas parental cells showed an approximately doubling in apoptosis levels after treatment with trastuzumab (P<0.01) ( Figure 3C ). In line with this result, Western blotting showed cleavage of caspase-3 in parental cells, but not in resistant cells after treatment with trastuzumab ( Figure 3D ). Together, these data indicated that t-DARPP expression counteracted trastuzumab-induced apoptosis in esophageal adenocarcinoma cells.
t-DARPP stabilizes ERBB2 protein and activates downstream signaling in response to trastuzumab
The cycloheximide (CHX)-based chase assay results indicated that stable expression of t-DARPP CAN-12-1119 AKT in OE19 cells ( Figure 4D) . Similarly, these results were confirmed in endogenous t-DARPP expression resistant cell model ( Figure 4E ). These data clearly demonstrated that t-DARPP expression maintained ERBB2 phosphorylation and activated the downstream AKT survival pathway in response to trastuzumab treatment. Of note, t-DARPP-mediated ERBB2 protein stability was associated with increased levels of ERBB2, p-ERBB2(Y1248), and p-AKT(S473) proteins in OE19 cells without treatment with trastuzumab ( Figures 4C -4E) .
Knockdown of endogenous t-DARPP sensitizes cells to trastuzumab
The Western blot analysis data indicated that knockdown of t-DARPP and treatment with trastuzumab significantly decreased p-ERBB2(Y1248) and p-AKT(S473) protein levels relative to controls ( Figure 5A ). Knocking down t-DARPP alone, without treatment with trastuzumab, decreased p-AKT(S473) protein level in OE33 cells ( Figure 5A ). The CellTiter-Glo viability assay results revealed that knockdown of t-DARPP in combination with trastuzumab treatment decreased cell survival by 30% relative to control (p<0.01) ( Figure 5B ). These results clearly demonstrated that knocking down endogenous t-DARPP in OE33 cells significantly sensitized cells to trastuzumab.
t-DARPP/ERBB2 protein interaction interferes with trastuzumab binding to ERBB2 receptor
We hypothesized that t-DARPP interacts with ERBB2, thus interfering with trastuzumab binding to ERBB2 receptor, and subsequently affecting downstream signaling. The results of two-way reciprocal immunoprecipitation assay showed that t-DARPP and ERBB2 co-immunoprecipitated, indicating their association in the same protein complex ( Figure 6A ). We next investigated the effect of t-DARPP expression on trastuzumab binding to ERBB2 receptor. Immunoprecipitation assay data showed that transiently expressed t-DARPP in OE19 cells decreased the trastuzumab binding to ERBB2 receptor by 2.8 fold relative to control cells ( Figure 6B) . Similarly, endogenous t-DARPP expression in trastuzumab resistant OE19 cells was associated with a 2.5-fold decrease in trastuzumab binding to ERBB2 relative to control cells ( Figure 6C ). To further confirm these data, we treated OE19 cells stably expressing t-DARPP or control vector with trastuzumab and a BS 3 crosslinking reagent. The immunofluorescence staining results showed that the trastuzumab-bound ERBB2 protein level was approximately 5 fold lower in t-DARPP-expressing cells than control cells (p<0.01) (Supplemental Figure 2) . In line with this finding, the immunofluorescence data demonstrated strong cytosolic expression of t-DARPP that also co-localized with the membranous ERBB2 signal. Of note, cells expressing higher levels of t-DARPP showed stronger ERBB2 signal (Supplemental Figure 2C) .
t-DARPP enhances tumor growth and inhibits response to trastuzumab in vivo
The results demonstrated that tumors derived from OE19 cells stably expressing t-DARPP failed to respond to trastuzumab treatment ( Figure 7A ). In contrast, trastuzumab effectively inhibited growth of control tumors ( Figure 7B 
Discussion
While the incidence of EAC has increased rapidly in the last decades, especially among Caucasian men, limited progress in the treatment of EAC has been achieved (31) . The prognosis of patients diagnosed with EAC remains poor with a 5-year relative survival at 10-20%. Over the past 15 years, targeted therapy approaches have made significant advances due to the rapid development of new drugs that aim treatment at specific molecular targets that are critical for cancer cell survival (32) . Amplification and overexpression of ERBB2 has been identified in 15-20% of primary EAC tumor specimens and their corresponding metastases (33, 34) . Therefore, in addition to breast cancer, ERBB2 has been suggested as a plausible target for treatment in esophageal cancers. Trastuzumab, a recombinant humanized monoclonal anti-ERBB2 antibody, was initially approved by the FDA for the treatment of ERBB2 metastatic breast carcinoma (19) . With its successful application in breast cancer, trastuzumab antitumor activity was investigated in patients with ERBB2-positive metastatic cancer of gastroesophageal junction in combination with chemotherapy (28) . Of note, a phase III clinical trial (RTOG 1010 protocol) is currently underway to evaluate the addition of trastuzumab to increase disease-free survival when combined with trimodality treatment for patients with ERBB2-positive esophageal adenocarcinoma. However, previous studies have shown that cancer patients who initially respond well to trastuzumab, develop acquired trastuzumab resistance within a year of treatment (20) . Our current study provides important pre-clinical evidence suggesting that t-DARPP could mediate trastuzumab resistance in EAC.
Our results indicate that both t-DARPP and ERBB2 were significantly overexpressed in a subset of EAC tumors. Moreover, overexpression of t-DARPP was significantly associated with advanced tumor stage. Of note, both ERBB2 and t-DARPP are located inside the 17q21 chromosomal region, a commonly amplified region in adenocarcinomas of the stomach and esophagus (33, 35) .
Several studies have shown that ERBB2 plays an important role in activation of the pro-survival PI3K/AKT signaling pathway (36) . Similarly, t-DARPP can also mediate activation of PI3K/AKT pathway (14) . Based on these data, we hypothesized that t-DARPP and ERBB2 may have a functional relationship where t-DARPP-mediated activation of AKT could lead to resistance to trastuzumab. The results indicated that endogenous and exogenous t-DARPP expression can significantly enhance cell survival and block apoptosis in response to trastuzumab in esophageal adenocarcinoma cell models.
The xenografted esophageal adenocarcinoma mouse model results confirmed the in vitro data and t-DARPP overexpressing tumors were unaffected by trastuzumab treatment and continued to grow.
These results confirmed the role of t-DARPP in mediating resistance to trastuzumab in EAC cells. Our finding that trastuzumab-resistant OE19 cells, generated by trastuzumab selection, expressed a significantly higher endogenous level of t-DARPP than parental cells provide an additional evidence supporting the role of t-DARPP in resistance to trastuzumab. Interestingly, a breast cancer trastuzumab-resistant cell model expressed higher levels of t-DARPP (37) . Taken together, these data suggest the possible presence of a small subpopulation of cells overexpressing t-DARPP among cancer cells where treatment with trastuzumab provides the appropriate selection advantage for this subpopulation to continue to grow and replace trastuzumab-sensitive cell populations.
While we and others have previously shown that t-DARPP can lead to activation of AKT and resistance to trastuzumab in breast cancer cells in vitro (14, 37) (38, 39) , the mechanism by which t-DARPP activates the AKT survival pathway was not fully identified. In the current study, our data clearly indicated that t-DARPP expression, without treatment with trastuzumab, significantly increased ERBB2, p-ERBB2(Y1248), and p-AKT(S473) protein levels relative to control cells. Notably, the trastuzumab-resistant OE19 cells showed, in addition to t-DARPP overexpression, increased p-ERBB2(Y1248) and p-AKT(S473) protein levels as compared to parental cells, consistent with our findings from transient and stable expression of t-DARPP. Taken together, these results indicate that t-DARPP can significantly enhance ERBB2 protein stability thereby enhancing the AKT pathway. The possibility that t-DARPP could also enhance the protein stability of other ERBB family members remains to be investigated in EAC.
Previous studies have shown that failure to suppress the AKT pathway plays central role in resistance to trastuzumab in breast cancer. Several mechanisms have been suggested such as activating mutations in the PI3KCA, deletions of PTEN, overexpression of cMET, and overexpression of ERBB3 (40, 41) . In an attempt to elucidate the mechanistic role of t-DARPP in trastuzumab resistance in EAC, we found that t-DARPP associated with ERBB2 in a protein complex. Based on this finding, we hypothesized that t-DARPP interaction with ERBB2 prevents trastuzumab binding to ERBB2 receptor, thus blocking trastuzumab-induced down-regulation of ERBB2/AKT signaling.
Indeed, our results clearly demonstrated that t-DARPP significantly decreased trastuzumab binding to the ERBB2 receptor in OE19 cells. The immunofluorescence data clearly indicated that t-DARPP expression was cytosolic (Supplemental Figure 2C) ; strongly suggesting that t-DARPP interaction with ERBB2 cytosolic domain could alter ERBB2 protein folding and conformation, thereby interfering with trastuzumab binding to ERBB2 extracellular domain. Nagy and colleagues (42) uncovered a similar mechanism of trastuzumab resistance in JIMT-1 breast cancer cells and showed that the expression of MUC4, a trans-membrane glycoprotein, promoted resistance to trastuzumab through masking of ERBB2, which leads to diminished binding of trastuzumab. These data suggest that molecular mechanisms that lead to the impairment of binding of trastuzumab to its target, ERBB2, are important upstream determinants of therapeutic response.
In conclusion, our findings indicate that frequent overexpression of t-DARPP in ERBB2-positive EAC underlies a trastuzumab resistance phenotype. Therefore, our data suggest that t- show that exogenous and endogenous t-DARPP significantly promoted cell survival in response to trastuzumab in OE19 cells. 
